- E-post
- synnove.yndestad@uib.no
- Besøksadresse
-
Haukeland universitetssykehus, Laboratoriebygget
5009 Bergen - Postadresse
-
Postboks 7804
5020 Bergen
Følg meg
Publikasjoner
Doktorgradsavhandling
Konferanseforedrag
Konferanseposter
- Hans Petter Eikesdal; Synnøve Yndestad; Egil Støre Blix et al. (2019). Neoadjuvant olaparib monotherapy in primary triple negative breast cancer. (ekstern lenke)
- Synnøve Yndestad; Irja Sunde Roiha; Vigdis Torsvik et al. (2002). Microbial community analysis of a hydrocarbon-contaminated arctic soil from Svalbard. (ekstern lenke)
- Synnøve Yndestad; Irja Sunde Roiha; Lise Øvreås et al. (2002). Oil pollution in the Arctic and its effect on microbial diversity and ecology. (ekstern lenke)
Vitenskapelig artikkel
- Christina Engebrethsen; Synnøve Yndestad; Mari Eskild Rasmussen et al. (2025). Neoadjuvant endocrine therapy with sequential palbociclib and chemotherapy based on Ki67 status in stage II-III breast cancer: An open-label, phase II study. (ekstern lenke)
- Synnøve Yndestad; Hans Kristian Haugland; Dorota Katarzyna Pazdyk Goplen et al. (2024). Germline variants in patients diagnosed with pediatric soft tissue sarcoma. (ekstern lenke)
- Oleksii Nikolaienko; Hans Petter Eikesdal; Elisabet Ognedal Berge et al. (2023). Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development. (ekstern lenke)
- Synnøve Yndestad; Christina Engebrethsen; A. Herencia-Ropero et al. (2023). Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer. (ekstern lenke)
- Hans Petter Eikesdal; Synnøve Yndestad; Asmaa Elzawahry et al. (2020). Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. (ekstern lenke)
- Synnøve Yndestad; Eilin Austreid; Kai Ove Skaftnesmo et al. (2018). Divergent activity of the pseudogene PTENP1 in ER-positive and negative breast cancer. (ekstern lenke)
- Synnøve Yndestad; Eilin Austreid; Ida Svanberg et al. (2017). Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines. (ekstern lenke)
- Synnøve Yndestad; Eilin Austreid; Stian Knappskog et al. (2017). High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function. (ekstern lenke)
- Eli Sihn Samdal Steinskog; Solfrid Johanne Sagstad; Marek Wagner et al. (2016). Impaired lymphatic function accelerates cancer growth. (ekstern lenke)
- Stian Knappskog; Elisabet Ognedal Berge; Ranjan Chrisanthar et al. (2015). Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo. (ekstern lenke)